Ironwood Pharmaceuticals, Inc. Class A (IRWD)

Over the past six months, Ironwood Pharmaceuticals' stock experienced a significant increase of 378.60%. Key events include the Q3 2025 earnings release with an EPS of $0.230 USD, the 2026 financial guidance release projecting significant revenue growth for LINZESS, the Q4 2025 earnings release with an EPS of -$0.010 USD, analyst rating changes from Zacks Research, Jefferies Financial Group, Citizens Jmp, and Wall Street Zen, insider selling, and the Q1 2026 earnings release with an EPS of $0.240 USD.

Information regarding specific demand seasonality for Ironwood Pharmaceuticals' products and services is not explicitly detailed. The company's financial reports indicate consistent demand growth for LINZESS, with an 11% increase in total prescription demand for the full year 2025 compared to 2024. However, this does not inherently suggest a seasonal pattern in demand.

Ironwood Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare diseases. Their flagship product is LINZESS (linaclotide), marketed in the U.S. for adults with IBS-C or CIC and approved for pediatric functional constipation. Linaclotide is also commercialized as CONSTELLA in select markets through collaborations. The company is advancing a pipeline of product candidates, including apraglutide for rare GI diseases, IW-3300 for visceral pain conditions, and CNP-104 for primary biliary cholangitis (PBC).

Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with operations in Basel, Switzerland. Linaclotide is commercially available in the United States, Mexico, Japan, and China under the LINZESS brand. Under the CONSTELLA brand, linaclotide is available in Canada and certain European countries.

Ironwood Pharmaceuticals' brand reputation has been influenced by its financial performance and pipeline developments. Positive sentiment was generated by the company's 2026 financial guidance, projecting significant growth for LINZESS sales and adjusted EBITDA. However, there have also been discussions reflecting a "rough year" for Ironwood, with some market participants questioning the sustainability of rallies in the volatile biotech sector. The consistent performance of LINZESS sales and the potential of their pipeline drugs like apraglutide are seen as bullish indicators.

Ironwood Pharmaceuticals, Inc. has a significant institutional ownership presence. As of May 2026, there are 213 institutional owners and shareholders holding a total of 156,701,993 shares, accounting for approximately 93.95% of the company. Major institutional shareholders include Armistice Capital, Llc, Vanguard Group Inc, Sarissa Capital Management LP, and BlackRock, Inc.